Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Apolipoprotein Clear all
Completed No phase listed Observational Accepts healthy volunteers

Gene-Environment Interactions in Alzheimer's Disease

NCT00018473
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

NCT00568594
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 15, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MIRAGE: Multi-Institutional Research in Alzheimer's Genetic Epidemiology

NCT00239759
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
12
States / cities
Birmingham, Alabama • Sun City, Arizona • Downey, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2009 · Synced Sep 15, 2026, 10:28 PM EDT
Recruiting Not applicable Interventional

Atlantic Lipid Lowering Treatment Optimization Program

NCT06439654
View directory record Official record
Conditions
Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Apolipoprotein B 100, Familial Defective, High Density Lipoprotein Deficiency, Low-Density-Lipoid-Type Hyperlipoproteinemia
Interventions
Supportive care
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 120 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Clark, New Jersey • Springfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Not applicable Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

NCT00348309
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
41
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 15, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lipoprotein Metabolism in Normal Volunteers and Patients With Abnormal Levels of Lipoproteins

NCT00001226
View directory record Official record
Conditions
Healthy, Hyperlipoproteinemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1987 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 15, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) II

NCT00089882
View directory record Official record
Conditions
Alzheimer Disease
Interventions
APOE Genetic susceptibility testing
Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin

NCT01133366
View directory record Official record
Conditions
Healthy
Interventions
warfarin sodium, mipomersen sodium; warfarin sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Sep 15, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Family Research Study: Metabolism of Fats and Proteins in Specific Ethnic Groups

NCT00853775
View directory record Official record
Conditions
Healthy, Heart Disease
Interventions
No intervention, observational study
Other
Lead sponsor
University of California, Davis
Other
Eligibility
6 Years and older
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lipid Challenge in Adults

NCT03948295
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Lipid Challenge
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

NCT01090661
View directory record Official record
Conditions
Healthy
Interventions
mipomersen sodium, moxifloxacin hydrochloride (Avelox®), placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Sep 15, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance

NCT01120860
View directory record Official record
Conditions
Age-related Cognitive Decline
Interventions
MRI
Device
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
45 Years to 100 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2011
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Lorazepam on Cognition in APOE e4 Carriers

NCT00586430
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
lorazepam, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Sep 15, 2026, 10:28 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of MEDI6012 on Apolipoprotein B100 Metabolism

NCT03773172
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
MEDI6012, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

NCT00574132
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
219
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 170 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 15, 2026, 10:28 PM EDT
Completed No phase listed Observational

The Occurrence of the ApoE4 Allele in Agitated In-Patients With Late-Onset Alzheimer's Disease

NCT01329536
View directory record Official record
Conditions
Alzheimer's Disease, Agitation
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Apolipoprotein CIII Reduction Via Colchicine

NCT02083510
View directory record Official record
Conditions
Hypertriglyceridemia, Gout, Pericarditis
Interventions
Colchicine
Drug
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

NCT01323153
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
dalcetrapib, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Pensacola, Florida • Saginaw, Michigan • Saint Cloud, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

NCT01604824
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 15, 2026, 10:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cannabis Effects on Brain Morphology in Aging

NCT01874886
View directory record Official record
Conditions
Study Focuses on Brain Morphology and Cognition in Older Subjects
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 15, 2026, 10:28 PM EDT
Completed No phase listed Observational

Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)

NCT01763892
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
5 Days to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Sep 15, 2026, 10:28 PM EDT
Terminated Phase 3 Interventional Results available

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

NCT00998764
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bapineuzumab 0.5 mg/kg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
51 Years to 90 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
66
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Sep 15, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00348140
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
49
States / cities
Sun City, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 15, 2026, 10:28 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

NCT00439972
View directory record Official record
Conditions
Contraception
Interventions
Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Sep 15, 2026, 10:28 PM EDT